Ambrx
La Jolla
About Ambrx
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $500.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (May 2023)
- Ticker: nyse:AMAM
- Website: ambrx.com
- Phone: (858)875-2479
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ambrx-81528 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.